In December 2022, the Omicron variant strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread in China (3). To dynamically monitor the epidemic trends and disease burden of COVID-19 in the general population and to promptly understand changes in public medical needs, the National Sentinel Community-Based Surveillance (NSCS) was launched under the support of the National Bureau of Disease Control and Prevention. This aimed to provide scientific evidence for improved prevention, control, and management of COVID-19 and enable the rational allocation of medical and health resources (2).
NSCS is a national community-based sentinel surveillance cohort consisting of a sample size of 0.42 million participants. It employed multistage stratified cluster sampling from all 31 provincial-level administrative divisions (PLADs) and the Xinjiang Production and Construction Corps (XPCC). Each PLAD selected one provincial capital city, one other large city, and one county. At least 2,000 households (≥5,000 individuals) were sampled in each provincial capital city; at least 1,500 households (≥3,000 individuals) were sampled in each selected large city; and at least 1,000 households (≥2,500 individuals) were sampled in each selected county (2). The minimum sampling unit was the household, and all selected households were included in the cohort. Each site conducted nucleic acid or antigen testing twice a week for every household. Additionally, information on symptoms, hospital visits, and other basic data were collected. NSCS collected data and provided feedback through multi-department collaboration. Community or village committees in each surveillance sentinel site were responsible for implementing the investigation and reporting data. The district CDC of each sentinel site was responsible for collecting information and reporting to other levels.
All participants in the monitored communities were tested for infection twice a week from December 16, 2022, to January 12, 2023. Data from the NSCS showed that the peak of SARS-CoV-2 infection in China had passed, and SARS-CoV-2 infection in community populations is currently at a low epidemic level (2). Specifically, the daily average newly positive rate of SARS-CoV-2 infection decreased from 4.13% in Round 1 (December 16–19, 2022) to 0.69% in Round 8 (January 10–12, 2023). The epidemic peak occurred in Round 2 (December 20–22, 2022) (2). In rural areas, the epidemic wave also peaked between December 20–22, 2022, and passed quickly following the optimization of prevention and control measures (4). Since January 13, participants have been tested once a week, given the low epidemic level of SARS-CoV-2 infection. The time interval and content of community-based surveillance have been adjusted and optimized according to the needs of disease prevention and control.